Phase 3 trial results for mRNA-4157 cancer recurrence therapy

A phase 3 clinical trial evaluating the mRNA-4157 vaccine in combination with pembrolizumab for preventing cancer recurrence has released initial findings. The efficacy of this combination therapy remains subject to full peer review and regulatory assessment, but it represents a significant development in personalized oncology treatments.